

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 20-F

(Mark One)

Registration statement pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934

or

Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the fiscal year ended December 31, 2008.

or

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

or

Shell company report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of event requiring this shell company report \_\_\_\_\_

Commission file number: 001-32371

**SINOVAC BIOTECH LTD.**  
(Exact name of Registrant as specified in its charter)

N/A  
(Translation of Registrant's name into English)

Antigua, West Indies  
(Jurisdiction of incorporation or organization)

No.39 Shangdi Xi Road,  
Haidian District, Beijing 100085  
People's Republic of China  
(Address of principal executive offices)

Helen G. Yang  
Manager of International Business Development  
No.39 Shangdi Xi Road,  
Haidian District, Beijing 100085  
People's Republic of China  
Tel: +86-10-6296-3661  
Fax: +86-10-6296-6910  
E-mail: yangg@sinovac.com

(Name, telephone, e-mail and/or facsimile number and address of company contact person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:  

<u>Title of each class</u>	<u>Name of each exchange on which registered</u>
Common Shares, per value \$0.001 per share	NYSE Amex

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None  
(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None  
(Title of Class)